FIZE Medical is thrilled to announce that we have successfully raised $14 million in our latest funding round, which will enable us to further advance our innovative solutions that are transforming the landscape of renal monitoring in healthcare. Our cutting-edge technology provides medical professionals with real-time monitoring of renal output, a vital sign that plays a critical role in assessing a patient's hemodynamic status in a variety of clinical environments, from operating rooms to critical care units. With this new funding, we aim to enhance the capabilities of our monitoring systems, ensuring that healthcare providers can detect and address potential complications in a timely manner. This crucial step not only improves patient outcomes but also reduces hospitalization-related complications, ultimately saving lives. The funds will also be allocated toward expanding our research and development efforts, solidifying our position as leaders in the medical technology space, and enabling us to bring our solutions to a broader market. We are excited about the journey ahead and are committed to equipping healthcare professionals with the tools they need to provide the highest level of care. Thank you to our investors for believing in our mission and joining us in our pursuit to revolutionize how renal health is monitored, enhancing patient safety and clinical efficiency in the process. Together, we are paving the way for a future where real-time data transforms the standard of care across healthcare systems worldwide.
Revolutionizing Healthcare: FIZE Medical Secures $14 Million in Funding for Advanced Renal Output Monitoring Technology
Get the full FIZE Medical company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Anveshan
We are a food-tech startup aiming to provide high quality deeply traceable food products. We leverage technologies based on image processing, spectroscopy, blockchain and IOT to provide the best quality food products made traditionally.
$12.7M Series b
today
Caseway
We are the only enterprise AI form platform that replaces internal R&D and manual workflows by building and maintaining fully integrated automation systems, aligned to your data, your processes, and your long-term success. For document-intensive, compliance-driven organizations in regulated industries like insurance, education, finance, healthcare, and government Compelling reason to buy: Who need AI and automation tailored to their unique forms, workflows, and security environment, without having to shoulder R&D risk or manage AI development internally Product category: Our product is an enterprise document form platform Key benefit: That delivers a fully integrated, continuously improving automation system, built and maintained by experts, without upfront AI build costs Key differentiation: Our product is custom-built for each client’s systems and documents, fully integrated and continuously improved through a long-term partnership model, we maintain, debug, adapt, and align incentives to make it work in the real world.
$1.5M Pre-seed
today
Kubera Health
Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.
$6.5M Seed
today
Psilera
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.
$8.8M Seed
today
Abstract
Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.
$59.0M Series a
today